Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2011

Open Access 01-12-2011 | Review

Gut microbiota and sirtuins in obesity-related inflammation and bowel dysfunction

Authors: Shaheen E Lakhan, Annette Kirchgessner

Published in: Journal of Translational Medicine | Issue 1/2011

Login to get access

Abstract

Obesity is a chronic disease characterized by persistent low-grade inflammation with alterations in gut motility. Motor abnormalities suggest that obesity has effects on the enteric nervous system (ENS), which controls virtually all gut functions. Recent studies have revealed that the gut microbiota can affect obesity and increase inflammatory tone by modulating mucosal barrier function. Furthermore, the observation that inflammatory conditions influence the excitability of enteric neurons may add to the gut dysfunction in obesity. In this article, we discuss recent advances in understanding the role of gut microbiota and inflammation in the pathogenesis of obesity and obesity-related gastrointestinal dysfunction. The potential contribution of sirtuins in protecting or regulating the circuitry of the ENS under inflamed states is also considered.
Appendix
Available only for authorised users
Literature
1.
Matsushita Y, Yoshiike F, Yoshita K, Takimoto H: Trends in childhood obesity in Japan over the last 25 years from the national nutrition survey. Obesity Res. 2004, 12: 205-214.
2.
Sasai H, Sairenchi T, Hiroyasu I, Irie F, Otaka E, Tanaka K, Ota H, Muto T: Relationship between obesity and incident diabetes in middle-aged and older Japanese adults: The Ibaraki prefectural health study. Mayo Clin Proc. 2010, 85: 36-40.PubMedCentralPubMed
3.
Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, Rimm E, Colditz GA: Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med. 2001, 161: 1581-1586.PubMed
4.
Delgado-Aros S, Locke GR, Camilleri M, Talley NJ, Fett S, Zinsmeister AR, Melton LJ: Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. Am J Gastroenterol. 2004, 99: 1801-1806.PubMed
5.
Snoek SA, Verstege MI, Boeckxstaens GE, van den Wijngaard RM, de Jonge WJ: The enteric nervous system as a regulator of intestinal epithelial barrier function in health and disease. Expert Rev Gastroenterol Hepatol. 2010, 4: 637-651.PubMed
6.
Hotamisligil GS: Inflammation and metabolic disorders. Nature. 2006, 444: 860-867.PubMed
7.
Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G: Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001, 280: E745-E751.PubMed
8.
Syrenicz A, Garanty-Bogachka B, Syrenicz M, Gebala A, Walczak M: Low-grade systemic inflammation and the risk of type 2 diabetes in obese children and adolescents. Neuro Endocrinol Lett. 2006, 27: 453-458.PubMed
9.
Panagiotakos DB, Pitsavos C, Yannakoulia M, Chrysohoou C, Stefanadis C: The implication of obesity and central fat on markers of chronic inflammation: The ATTICA study. Atherosclerosis. 2005, 183: 308-315.PubMed
10.
Viser M, Bouter LM, McQuillan GM, Wener MH, Harris TB: Low-grade systemic inflammation in overweight children. Pediatrics. 2001, 107: E13-
11.
Brake DK, Smith EO, Mersmann H, Smith CW, Robker RL: ICAM-1 expression in adipose tissue: effects of diet-induced obesity in mice. Am J Physiol Cell Physiol. 2006, 291: C1232-1239.PubMed
12.
Kim SJ, Choi Y, Choi YH, Park T: Obesity activates toll-like receptor-mediated proinflammatory signaling cascades in the adipose tissue of mice. J Nutr Biochem. 2011
13.
Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003, 1123: 1821-1830.
14.
DiBaise JK, Zhang H, Crowell MD, Krajmalnik-Brown R, Decker GA, Rittmann BE: Gut microbiota and its possible relationship with obesity. Mayo Clin Proc. 2008, 83: 460-469.PubMed
15.
Conterno L FF, Viola R, Tuohy KM: Obesity and the gut microbiota: does up-regulating colonic fermentation protect against obesity and metabolic disease?. Genes Nutr. 2011, 6: 241-260.PubMedCentralPubMed
16.
Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI: The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci. 2004, 101: 15718-15723.PubMedCentralPubMed
17.
de La Serre CB, Ellis CL, Lee J, Hartman AL, Rutledge JC, Raybould HE: Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am J Physiol Gastrointest Liver Physiol. 2010, 299: G440-448.PubMedCentralPubMed
18.
Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, Gibson GR, Delzenne NM: Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007, 50: 2374-2383.PubMed
19.
Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R: Changes in gut microbiota could control endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008, 57: 1470-1481.PubMed
20.
Cani PD, Delzenne NM, Amar J, Burcelin R: Role of gut microflora in the development of obesity and insulin resistance following high-fat diet feeding. Pathol Biol (Paris). 2008, 56: 305-309.
21.
Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM: Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009, 58: 1091-1103.PubMedCentralPubMed
22.
Griffiths EA, Duffy LC, Schanbacher FL, Qiao H, Dryja D, Leavens A, Rossman J, Rich G, Dirienzo D, Ogra PL: In vivo effects of bifidobacteria and lactoferrin on gut endotoxin concentration and mucosal immunity in Balb/c mice. Dig Dis Sci. 2004, 49: 579-589.PubMed
23.
Wang Z, Xiao G, Yao Y, Guo S, Lu K, Sheng Z: The role of bifidobacteria in gut barrier function after thermal injury in rats. J Trauma. 2006, 61: 650-657.PubMed
24.
Brun P, Castagliuolo I, Di Leo V, Buda A, Pinzani M, Palu G, Martines D: Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2007, 292: G518-G525.PubMed
25.
Scarpellini E, Campanale M, Leone D, Purchiaroni F, Vitale G, Lauritano EC, Gasbarrini A: Gut microbiota and obesity. Intern Emerg Med. 2010, 5 (Suppl 1): S53-56.PubMed
26.
Santacruz A, Marcos A, Wärnberg J, Martí A, Martin-Matillas M, Campoy C, Moreno LA, Veiga O, Redondo-Figuero C, Garagorri JM: Interplay between weight loss and gut microbiota composition in overweight adolescents. Obesity. 2009, 17: 1906-1915.PubMed
27.
Chaudhri O, Wynne K, Bloom SR: Can gut hormones control appetite and prevent obesity?. Daibetes Care. 2008, 31 (Suppl 2): S284-S289.
28.
Furet JP, Kong LC, Tap J, Poitou C, Basdevant A, Bouillot JL, Mariat D, Corthier G, Doré J, Henegar C: Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation. Diabetes. 2010, 59: 3049-3057.PubMedCentralPubMed
29.
Kelly G: A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 2. Alt Med Rev. 2010, 15: 313-338.
30.
Schug TT, Li X: Sirtuin 1 in lipid metabolism and obesity. Ann Med. 2011
31.
Greiner T, Backhed F: Effects of the gut microbiota on obesity and glucose homeostasis. Trends Endocrinol Metab. 2011
32.
Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, Keilbaugh SA, Hamady M, Chen YY, Knight R, Ahima RS, Bushman F, Wu GD: High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology. 2009, 137: 1716-1724.PubMedCentralPubMed
33.
Backhed F: Changes in intestinal microflora in obesity: cause or consequence?. J Pediatr Gastroenterol Nutr. 2009, 48 (Suppl 2): S56-S57.PubMed
34.
Turnbaugh PJ, Bäckhed F, Fulton L, Gordon JI: Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe. 2008, 3: 213-223.PubMedCentralPubMed
35.
Damaskos D, Kolios G: Probiotics and prebiotics in inflammatory bowel disease: microflora "on the scope". Br J Clin Pharmacol. 2008, 65: 453-467.PubMedCentralPubMed
36.
Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI: Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci. 2007, 104: 979-984.PubMedCentralPubMed
37.
Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI: Obesity alters gut microbial ecology. Proc Natl Acad Sci. 2005, 102: 11070-11075.PubMedCentralPubMed
38.
Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI: An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006, 444: 1027-1031.PubMed
39.
Bjursell M, Admyre T, Goransson M, Marley AE, Smith DM, Oscarsson J, Bohlooly-Y M: Improved glucose control and reduced body fat mass in free fatty acid recepto 2-deficient mice fed a high-fat diet. Am J Physiol Endocrinol Metab. 2011, 300: E211-220.PubMed
40.
Ley RE, Turnbaugh PJ, Klein S, Gordon JI: Microbial ecology: human gut microbes associated with obesity. Nature. 2006, 444: 1022-1023.PubMed
41.
Zhang H, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, Yu Y, Parameswaran P, Crowell MD, Wing R, Rittmann BE: Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci USA. 2009, 106: 2365-2370.PubMedCentralPubMed
42.
Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP: A core gut microbiome in obese and lean twins. Nature. 2009, 457: 480-484.PubMedCentralPubMed
43.
Kalliomaki M, Collado MC, Salminen S, Isolauri E: Early differences in fecal microbiota composition in children may predict overweight. Am J Clin Nutr. 2008, 87: 534-538.PubMed
44.
Collado MC IE, Laitinen K, Salminen S: Distinct composition of gut microbiota during pregnancy in overweight and normal-weight women. Am J Clin Nutr. 2008, 88: 894-899.PubMed
45.
Wu X MC, Han L, Nawaz M, Gao F, Zhang S, Yu P: Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol. 2010, 61: 69-78.PubMed
46.
Lupp C, Robertson ML, Wickham ME, Sekirov I, Champion OL, Gaynor EC, Finlay BB: Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe. 2007, 2: 119-129.PubMed
47.
Frost WJ: Antibiotics and animal production. Microbiology of Animals and Animal Products. Edited by: JB W. 1991, New York: Elsevier, 181-194.
48.
Lin J: Effect of antibiotic growth promoters on intestinal microbiota in food animals: a novel model for studying the relationship between gut microbiota and human obesity?. Front Microbiol. 2011, 2: 53-PubMedCentralPubMed
49.
Thuny F R, Casalta JP, Angelakis E, Habib G, Raoult D: Vancomycin treatment of infective endocarditis is linked with recently acquired obesity. PLOS One. 2010, 5: e9074-PubMedCentralPubMed
50.
Membrez M, Blancher F, Jaquet M, Bibiloni R, Cani PD, Burcelin RG, Corthesy I, Macé K, Chou CJ: Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB. 2008, 22: 2416-2426.
51.
Koo HL, HL DuPont: Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol. 2010, 26: 17-25.PubMed
52.
Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP: Rifaximin therapy for patients with irritable bowel syndrome without constipation. NEJM. 2011, 364: 22-32.PubMed
53.
Fain J: Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: A review. Mediators Inflamm. 2010
54.
Ding S, Chi MM, Scull BP, Rigby R, Schwerbrock NM, Magness S, Jobin C, Lund PK: High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. PLOS ONE. 2010, 5: e12191-PubMedCentralPubMed
55.
Erridge C, Attina T, Spickett CM, Webb DJ: A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr. 2007, 86: 1286-1292.PubMed
56.
Ghanim H, Abuaysheh S, Sia CL, Korzeniewski K, Chaudhuri A, Fernandez-Real J, Dandona P: Increase in plasma endotoxin concentrations and the expression of toll-like receptors and suppressor of cytokine signling-3 in mononuclear cells after a high-fat, high-carbohydrate meal. Diabetes Care. 2009, 32: 2281-2287.PubMedCentralPubMed
57.
Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C: Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007, 56: 1761-1772.PubMed
58.
Anderson PD, Mehta NN, Wolfe ML, Hinkle CC, Pruscino L, Comiskey LL, Tabita-Martinez J, Sellers KF, Rickels MR, Ahima RS: Innate immunity modulates adipokines in humans. J Clin Endocrinol Metab. 2007, 92: 2272-2279.PubMed
59.
Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, Sitaraman SV, Knight R, Ley RE, Gewirtz AT: Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science. 2010, 328: 228-231.PubMed
60.
Katz KD, Hollander D, Vadheim CM, McElree C, Delahunty T, Dadufalza VD, Krugliak P, Rotter JI: Intestinal permeability in patients with Crohn's disease and their healthy relatives. Gastroenterology. 1989, 97 (4): 927-931.PubMed
61.
Gribar SC, Richardson WM, Sodhi CP, Hackam DJ: No longer an innocent bystander: epithelial toll-like receptor signaling in the development of mucosal inflammation. Mol Med. 2008, 14 (9-10): 645-659.PubMedCentralPubMed
62.
Bruewer M, Luegering A, Kucharzik T, Parkos CA, Madara JL, Hopkins AM, Nusrat A: Proinflammatory cytokines disrupt epithelial barrier function by apoptosis independent mechanisms. J Immunol. 2003, 171: 6164-6172.PubMed
63.
Ohland CL, Macnaughton WK: Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol. 298 (6): G807-819.
64.
Bixquert Jimenez M: Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last?. Rev Esp Enferm Dig. 2009, 101 (8): 553-564.PubMed
65.
Guyonnet D, Chassany O, Ducrotte P, Picard C, Mouret M, Mercier CH, Matuchansky C: Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther. 2007, 26: 475-486.PubMed
66.
Kondo S, Xiao J-Z, Satoh T, Odamaki T, Takahashi S, Sugahara H, Yaeshima T, Iwatsuki K, Kamei A, Abe K: Antiobesity effects of Bifidobacterium breve strain B-3 supplementation in a mouse model with high-fat diet-induced obesity. Biosci, Biotechnol, Biochem. 2010, 74: 1656-1661.
67.
Kunze WA MY, Wang B, Huizinga JD, Ma X, Forsythe P, Bienenstock J: Lactobacillus reuteri enhances excitability of colonic AH neurons by inhibiting calcium-dependent potassium channel opening. J Cell Mol Med. 2009, 13: 2261-2270.PubMed
68.
Ma X MY, Wang B, Huizinga JD, Bienenstock J, Kunze W: Lactobacillus reuteri ingestion prevents hyperexcitability of colonic DRG neurons induced by noxious stimuli. Am J Physiol Gastrointest Liver Physiol. 2009, 296: G868-875.PubMed
69.
McKeman DP FP, Dinan TG, Cryan JF: The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat. Neurogastroenterol Motil. 2010, 22: 1029-1035.
70.
Bar F VKH, Roblick U, Bruch HP et al: Cell-free supernatants of Escherichia coli Nissle 1917 modulate human colonic motility; evidence from an in vitro organ bath study. Neurogastroenterol Motil. 2009, 21: 559-566.PubMed
71.
Wang B MY, Diorio C, Wang L, Huizinga JD, Bienenstock J, Kunze W: Lactobacillus reuteri ingestion and IK(Ca) channel blockade have similar effects on rat colon motility and myenteric neurons. Neurogastroenterol Motil. 2010, 22: 98-107.PubMed
72.
Levy RL, Linde JA, Feld KA, Crowell MD, Jeffery RW: The association of gastrointestinal symptoms with weight, diet, and exercise in weight-loss program participants. Clin Gastroenterol Hepatol. 2005, 3: 992-996.PubMed
73.
Talley NJ, Howell S, Poulton R: Obesity and chronic gastrointestinal tract symptoms in young adults: a birth cohort study. Am J Gastroenterol. 2004, 99: 1807-1814.PubMed
74.
Verdich C, Madsen JL, Toubro S, Buemann B, Holst JJ, Astrup A: Effect of obesity and major weight reduction on gastric emptying. Int J Obes Relat Metab Disord. 2000, 24: 899-905.PubMed
75.
Ashburn DD, Reed MJ: Gastrointestinal system and obesity. Crit Care Clin. 2010, 26: 625-627.PubMed
76.
Moayyedi P: The epidemiology of obesity and gastrointestinal and other diseases: an overview. Dig Dis Sci. 2008, 53: 2293-2299.PubMed
77.
Choi CW, Kim GH, Song CS, Wang SG, Lee BJ IH, Kang DH, Song GA: Is obesity associated with gastropharngeal reflux disease?. World J Gastroenterl. 2008, 14: 265-271.
78.
Dore MP, Maragkoudakis E, Fraley K, Pedroni A, Tadeu V, Realdi G, Graham DY, Delitala G, Malaty HM: Diet, lifestyle, and gender in gastro-esophageal reflux disease. Dig Dis Sci. 2008, 53: 2027-2032.PubMed
79.
Dickman R, Feroze H, Fass R: Gastroesophageal reflux disease and irritable bowel syndrome: a common overlap syndrome. Curr Gastroenterol Rep. 2006, 8: 261-265.PubMed
80.
Nocon M, Labenz J, Jaspersen D, Meyer-Sabellek W, Stolte M, Lind T, Malfertheiner P, Willich SN: Association of body mass index with heartburn, regurgitation and esophagitis: results of the progression of gastroesophageal reflux disease study. J Gastroenterol Hepatol. 2007, 22: 1728-1731.PubMed
81.
Schmulson M, Pulido D, Escobar C, Farfan-Labone B, Lopez-Alvarenga JC: Heartburn and other related symptoms are independent of body mass index in irritable bowel syndrome. Rev Exp Enferm Dig (Madrid). 2010, 102: 229-233.
82.
John BJ, Irukulla S, Abulafi AM, Kumar D, Mendall MA: Systematic review: adipose tissue, obesity and gastrointestinal diseases. Aliment Pharmacol Ther. 2006, 23: 1511-1523.PubMed
83.
Bassett JK, Severi G, English DR, Bagietto L, Krishnan K, Hopper JL, Giles GG: Body size, weight change, and risk of colon cancer. Cancer Epediemiol Biomarkers Prev. 2010, 19: 2978-2986.
84.
Stachowicz M, Mazurek U, Nowakowska-Zajdel E, Niedworok E, Fatyga E, Muc-Wierzgon M: Leptin and its receptors in obese patients with colorectal cancer. J Biol Regul Homeost Agents. 2010, 24: 287-295.PubMed
85.
Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Silva C, Rotellar F, Hernández-Lizoain JL, Baixauli J, Valentí V, Pardo F: Up-regulation of the novel proinflammatory adipokines lipocalin-2, chitinase-3 like 1 and osteopontin as well as angiogenic-related factors in visceral adipose tissue of patients with colon cancer. J Nutr Biochem. 2010
86.
Padidar S, Farquharson AJ, Williams LM, Kelaiditi E, N. H, Arthur JR, Drew JE: Leptin upregulates pro-inflammatory cytokines in discrete cells within mouse colon. J Cell Physiol. 2010
87.
Pendyala S, Neff LM, Suarez-Farinas M, Holt PR: Diet-induced weight loss reduces colorectal inflammation: implications for colorectal carcinogenesis. Am J Clin Nutr. 2010
88.
Bonilla S, Wang D, Saps M: Obesity predicts persistence of pain in children with functional gastrointestinal disorders. Int J Obes (Lond). 2010
89.
Venkatasubramani N, Telega G, Werlin SL: Obesity in pediatric celiac disease. J Pediatr Gastroenterol Nutr. 2010, 51: 295-297.PubMed
90.
Furness J: The enteric nervous system: normal functions and enteric neuropathies. Neurogastroenterol Motil. 2008, 20 (Suppl 1): 32-38.PubMed
91.
Mawe GM SD, Sharkey KA: Plasticity of enteric nerve functions in the inflamed and postinflamed gut. Neurogastroenterol Motil. 2009, 21: 481-491.PubMedCentralPubMed
92.
93.
Geboes K, Collins S: Structural abnormalities of the nervous system in Crohn's disease and ulcerative colitis. Neurogastroenterol Motil. 1998, 10: 189-202.PubMed
94.
Bernardini N, Segnani C, Ippolito C, De Griogio R, Colucci R, Faussone-Pellegrini MS, Chiarugi M, Campani D, Castagna M, Mattii L: Immunohistochemical analysis of myenteric ganglia and interstitial cells of Cajal in ulcerative colitis. J Cell Mol Med. 2011
95.
De Giorgio R, Camilleri M: Human enteric neuropathies: morphology and molecular pathology. Neurogastroenterol Motil. 2004, 16 (5): 515-531.PubMed
96.
Tornblom H, Lindberg G, Nyberg B, Veress B: Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology. 2002, 123 (6): 1972-1979.PubMed
97.
Hoffman JM MN, Sharkey KA, Mawe GM: The relationship between inflammation-induced neuronal excitability and disrupted motor activity in the guinea pig distal colon. Neurogastroenterol Motil. 2011, 23: 673-PubMed
98.
Dunlop SP, Jenkins D, Spiller RC: Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol. 2003, 98 (7): 1578-1583.PubMed
99.
Isgar B, Harman M, Kaye MD, Whorwell PJ: Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut. 1983, 24 (3): 190-192.PubMedCentralPubMed
100.
Hyland NP, Rybicka JM, Ho W, Pittman QJ, Macnaughton WK, Sharkey KA: Adaptation of intestinal secretomotor function and nutrient absorption in response to diet-induced obesity. Neurogastroenterol Motil. 2010, 22: 602-e171.PubMed
101.
Sullivan A, Nord CE, Evengard B: Effect of supplement with lactic-acid producing bacteria on fatigue and physical activity in patients with chronic fatigue syndrome. Nutr J. 2009, 8: 4-PubMedCentralPubMed
102.
Mostoslavsky R, Chua KF, Lombard DB, Pang WW, Fischer MR, Gellon L LP, Mostoslavsky G, Franco S, Murphy MM, Mills KD: Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell. 2006, 124: 315-329.PubMed
103.
Xiao C, Kim HS, Lahusen T, Wang RH, Xu X, Gavrilova O, Jou W, Gius D, Deng CX: SIRT6 deficiency results in severe hypoglycemia by enhancing both basal and insulin-stimulated glucose uptake in mice. J Biol Chem. 2010, 285: 36776-36784.PubMedCentralPubMed
104.
Kanfi Y, Peshti V, Gil R, Naiman S, Nahum L, Levin E, Kronfeld-Schor N, Cohen HY: SIRT6 protects against pathological damage caused by diet-induced obesity. Aging Cell. 2010, 9: 162-173.PubMed
105.
Schwer B, Schumacher B, Lombard DB, Xiao C, Kurtev MV, Gao J, Schneider JI, Chai H, Bronson RT, Tsai LH: Neural sirtuin 6 (Sirt6) ablation attenuates somatic growth and causes obesity. PNAS. 2010, 107: 21790-21794.PubMedCentralPubMed
106.
Kendrick AA, Choudhury M, Rahman SM, McCurdy CE, Friederich M, Van Hove JL, Watson PA, Birdsey N, Bao J, Gius D: Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation. Biochem J. 2011, 433: 505-514.PubMedCentralPubMed
107.
Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL: Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003, 425: 191-196.PubMed
108.
Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M, Sinclair D: Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature. 2004, 430: 686-689.PubMed
109.
Kim S, Jin Y, Choi Y, Park T: Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. Biochem Pharmacol. 2011
110.
Qiao I, Shao J: Sirt1 regulates adiponectin gene expression through Foxo1-C/EBPalpha transcriptional complex. J Biol Chem. 2006, 281: 39915-39924.PubMed
111.
Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, Machado De Oliveira R, Leid M, McBurney MW, Guarente L: Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature. 2004, 429: 771-776.PubMedCentralPubMed
112.
Pedersen SB, Olholm J, Paulsen SK, Bennetzen MF, Richelsen B: Low Sirt1 expression, which is upregulated by fasting, in human adipose tissue from obese women. Int J Obes (Lond). 2008, 32: 1250-1255.
113.
Peeters AV, Beckers S, Verrijken A, Mertens I, Roevens P, Peeters PJ, Van Hul W, Van Gaal LF: Association of SIRT1 gene variation with visceral obesity. Hum Genet. 2008, 124: 431-436.PubMed
114.
Zillikens MC, van Meurs JBJ, Rivadeneira F, Amin N, Hofman A, Oostra Ba, Sijbrands EJ, Witteman JC, Pols HA, van Duijn CM: SIRT1 genetic variation is related to BMI and risk of obesity. Diabetes. 2009, 58: 2828-2834.PubMedCentralPubMed
115.
Zhu J, Yong W, Wu X, Yu Y, Lv J, Liu C, Mao X, Zhu Y, Xu K, Han X: Anti-inflammatory effect of resveratrol on TNF-a-induced MCP-1 expression in adipocytes. Biochem Biophys Res Commun. 2008, 369: 471-477.PubMed
116.
Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschop MH: Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci. 2008, 105: 9793-9798.PubMedCentralPubMed
117.
Fischer-Posovszky P, Kukulus V, Tews D, Unterkircher T, Debatin KM, Fulda S, Wabitsch M: Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. Am J Clin Nutr. 2010, 92: 5-15.PubMed
118.
Yoshizaki T, Milne JC, Imamura T, Schenk S, Sonoda N, Babendure JL, Lu JC, Smith JJ, Jirousek MR, Olefsky JM: Sirt1 exerts anti-inflammatory effect and improves insulin sensitivity in adipocytes. Mol Cell Biol. 2009, 29: 1363-1374.PubMedCentralPubMed
119.
Ramadori G, Lee CE, Bookout AL, Lee S, Williams KW, Anderson J, Elmquist JK, Coppari R: Brain SIRT1: anatomical distribution and regulation by energy availability. J Neurosci. 2008, 28: 9989-9996.PubMedCentralPubMed
120.
Cakir I, Perello M, Lansari O, Messier NJ, Vaslet CA, Nillni EA: Hypothalmaic SIRT1 regulates food intake in a rodent model system. PLOS ONE. 2009, 4: e8322-PubMedCentralPubMed
121.
Ramadori G, Fujikawa T, Fukuda M, Anderson J, Morgan DA, Mostoslavsky R, Stuart RC, Perello M, Vianna CR, Nillni EA: SIRT1 deacetylase in POMC neurons is required for homeostatic defenses against diet-induced obesity. Cell Metab. 2010, 12-
122.
Bereswill S, Muñoz M, Fischer A, Plicket R, Haag LM, Otto B, Kühl AA, Loddenkemper C, Göbel UB, Heimesaat MM: Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation. PLOS One. 2010, 5: e15099-PubMedCentralPubMed
123.
Hofseth LJ, Singh UP, Singh NP, Nagarkatti M, Nagarkatti PS: Taming the beast within: resveratrol suppresses colitis and prevents colon cancer. Aging. 2010, 2: 183-184.PubMedCentralPubMed
124.
Larrosa M, Yanez-Gascon MJ, Selma MV, Gonzalez-Sarrias A, Toti S, Ceron JJ, Tomas-Bareran F, Dolara P, JC E: Effect of low dose of dietary resveratrol on colon microbiota, inflammation and tissue damage in a DSS-induced colitis rat model. J Agric Food Chem. 2009, 57: 2211-2220.PubMed
125.
Cani PD, Delzenne NM: Involvement of the gut microbiota in the development of low grade inflammation associated with obesity: focus on this neglected partner. Acta Gastroenterol Belg. 2010, 73: 267-269.PubMed
126.
Vanamala J, Tarver CC, Murano PS: Obesity-enhanced colon cancer: functional food compounds and their mechanisms of action. Curr Cancer Drug Targets. 2008, 8: 611-633.PubMed
127.
Bernard CE, Gibbons SJ, Gomez-Pinilla PJ, Lurken MS, Schmalz PF, Roeder JL, Linden D, Cima RR, Dozois EJ, Larson DW: Effect of age on the enteric nervous system of the human colon. Neurogastroenterol Motil. 2009, 21: 746-747.PubMedCentralPubMed
128.
Liu M, Kirchgessner AL: Agonist- and reflex-evoked internalization of metabotropic glutamate receptor 5 in enteric neurons. J Neurosci. 2000, 20: 3200-3205.PubMed
Metadata
Title
Gut microbiota and sirtuins in obesity-related inflammation and bowel dysfunction
Authors
Shaheen E Lakhan
Annette Kirchgessner
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2011
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-9-202

Other articles of this Issue 1/2011

Journal of Translational Medicine 1/2011 Go to the issue

Research

Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer

Research

High Chromosome Number in hematological cancer cell lines is a Negative Predictor of Response to the inhibition of Aurora B and C by GSK1070916

Research

Induction of Th1Immune responses following laser ablation in a murine model of colorectal liver metastases

Review

Expression of the Epigenetic factor BORIS (CTCFL) in the Human Genome

Research

Astrocyte elevated gene-1 (AEG-1) is a marker for aggressive salivary gland carcinoma

Editorial

How scientists use social media to communicate their research
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits